PHAR SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Pharming Group

On May 7, 2026, Pharming Group's CEO reaffirmed full-year revenue guidance of $405 million to $425 million. Twelve weeks later, the Company cut that range to $375 million to $395 million and the stock fell 22%. NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Pharming Group (NASDAQ: PHAR)...